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Background: Duguelin is a rotenoid extracted from plants and has potent antitumor effects in vitro and in vivo.
However, the mechanism underlying the antitumor effect remains unclear. Our preliminary study showed that
Deguelin is effective to stimulate the generation of Reactive Oxygen Species (ROS). In the current study, we
evaluated the in vitro cytotoxicity of Deguelin against lung cancer cells and studied whether a ROS scavenger,
N-acetyl-cysteine (NAC), can reverse the inhibitory effect of Deguelin.
Results: We showed that the dose-dependent apoptotic inducing effect of Deguelin could be partially reversed
by the co-administration of NAC. Moreover, Deguelin reduced the phosphorylation of Akt protein and induced
the apoptotic protein Caspase-3 in a dose-dependent manner. Co-treatment with NAC partially attenuated this
effect and rescued some cells from apoptosis.
Conclusion: Deguelin induces the apoptosis of cancer cells through a ROS driven Akt pathway, which could
translate into a promising therapeutic for lung cancer.
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Lung cancer remains the leading cause of cancer related
death all over the world [1]. However, traditional chemo-
therapy treatments often lead to severe toxicity and may
encounter the emerging resistance [2]. Therefore, it is
urgent to identify alternative drugs to chemotherapeutics
with lower toxicity and substantial antitumor effect.
Deguelin, a rotenoid extracted from the African plant
Mundulea sericea, has been reported to inhibit the
in vitro and in vivo growth of several types of tumors,
including lung, gastric, breast, colon and rectal cancer
etc. [3-7]. The possible mechanism may involve DNA
damage and repair gene suppression and regulation of
tumor specific pathways [5,6,8]. Additionally, Deguelin
has been demonstrated to induce the apoptosis of tumor
cells by inactivating Akt phosphorylation [9,10]. As a
survival signal, activation of the Akt pathway renders
cells resistant to apoptosis through regulation of pro-
apoptotic and anti-apoptotic proteins [11-13]. Previous* Correspondence: hongwang@njmu.edu.cn; wpxie@njmu.edu.cn
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unless otherwise stated.studies have shown that targeting the Akt pathway ef-
fectively inhibits the proliferation of cancer cells and sig-
nificantly delays tumor growth [12,13].
Reactive oxygen species (ROS), a natural byproduct of
the normal metabolism of oxygen plays a significant role
in a number of normal biochemical functions and abnor-
mal pathological processes [14]. There is a subtle bal-
ance between intracellular ROS and antioxidant capacity
in normal cells, which determines their destiny [15]. Yet
cancer cells are characterized of elevated intrinsic ROS
stress, resulting from carcinogenesis stimulation, abnor-
mal metabolic activity, and mitochondrial malfunction
[16,17]. The limited capacity of the tumor cells to deal
with the elevating ROS levels makes them vulnerable to
oxidative stress [16]. This embarks a novel strategy for
cancer therapy of promoting apoptosis of cancer cells by
eliminating the ability of antioxidant defense systems
through inducing ROS production [18,19].
In our preliminary studies, we showed that Deguelin
affects the redox state by inducing intracellular reactive
oxygen species (ROS) generation. Moreover, there is
substantial evidence showing that ROS is an upstream
signal of the Akt pathway [20-22]. The effect of both
Akt pathway inhibition and oxidative stress combine tois an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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detailed report, however, about the influence of Deguelin
on intracellular ROS earlier in paper since ROS is con-
sidered as an upstream signal to the Akt pathway. We
hypothesized that Deguelin may induce cellular apop-
tosis through induction of ROS, which may suppress the
downstream Akt pathway contributing to the cell death.
Here we investigated the antitumor effect of Deguelin
and the underlying mechanisms in non small cell lung
cancer cell line NCI-1975. Our results strongly suggest
that ROS-driven Akt dephosphorylation was vital to the
antitumor effect of Deguelin, which could be partially re-
versed by an antioxidant NAC.
Results
Elevation of intracellular ROS levels by Deguelin
Intracellular ROS levels were evaluated by FACS with
H2DCF-DA as a fluorescent probe. Shown in Figure 1A,
Deguelin induced the generation of ROS in a dose-
dependent manner, which was partially blocked by co-
treatment with NAC. For example, a nearly 10% reduction
in ROS levels was observed in the cells receiving 50 μMFigure 1 Intracellular ROS induction and in vitro cytotoxicity of Degu
cells induced by Deguelin with or without the presence of NAC. # represents
treatment of NAC. ** represents p < 0.01 vs the control cells. Data are pre
or without the presence of NAC in NCI-1975 cells after 24 h incubation. #
and with the treatment of NAC. * represents p < 0.05 vs the control cells.Deguelin plus NAC in comparison to the corresponding
dose of Deguelin alone. The reversal effect of NAC on
ROS production seems to be weak, but statistical analyasis
showed that there was a significant difference in ROS
levels between Deguelin alone and combined delivery of
Deguelin and NAC (p < 0.05).Deguelin induces the apoptosis of NCI-1975 cells in a
ROS-dependent manner
It is shown in Figure 1B by the MTT assay that cell via-
bility decreased with the concentration of Deguelin in-
creasing. Moreover, the dose dependent inhibitory effect
of Deguelin on NCI-1975 cells was partially but statisti-
cally significantly reversed by the antioxidant NAC. As
calculated from the bar graph, the IC50 value of Deguelin
was 42.6 μM while that of Deguelin with the co-treatment
of NAC was 54.7 μM. There was a significant difference
between the cytoxicity of Deguelin with and without the
co-incubation of NAC (p < 0.05). In addition, we tested
the cytotoxicity of Deguelin on another kind of lung
cancer line NCI-H446. It showed the same trend as onelin. A: Quantitative intracellular DCF fluorescence intensity of NCI-1975
p < 0.05 vs the corresponding dose between cells without and with the
sented as mean ± SD (n = 3). B: Cell cytotoxicity test of Deguelin with
represents p < 0.05 vs the corresponding dose between cells without
Data are represented as Mean ± SD (n = 3).
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(Suppl. Figure 1).
The anti-growth effect of Deguelin was also measured
by double staining with Edu and Hoechest 33432, which
simultaneously manifested the proliferating (Red staining
by Edu) and apoptotic (Bright Blue staining by Hoechest
33432) cells, respectively. As shown from Figure 2A,
there was an obvious dose-dependent decrease in the
number of proliferating cells as well as a substantial in-
crease in apoptotic cells when cells were treated by a
series of doses of Deguelin. Most importantly, the cytotox-
icity of Deguelin was attenuated by the co-administration
of NAC, which is consistent with the results from cyotoxi-
city studies.
The quantitative analysis of cell proliferation and
apoptosis (Figure 2B) also indicated that Deguelin dose-
dependently inhibited the proliferation and induced the
apoptosis of NCI-1975 cells, which could be counteracted
by the co-administration of NAC. Statistical analysis re-
vealed that co-treatment of NAC with Deguelin signifi-
cantly increase the percentage of proliferating cells
compared to Deguelin treatment alone (p < 0.05).
In addition, cellular apoptosis induced by Deguelin was
also measured by FACS quantitatively, which showed
the same trend observed in both cytotoxicity and prolif-
eration assays (Figure 3A). Increasing the concentration
of Deguelin led to an elevation of cellular apoptosis,
which was significantly reversed by co-treatment with
NAC (p < 0.05 vs Deguelin alone) (Figure 3B). More-
over, it is interesting that Deguelin increases the num-
ber of late apoptotic (necrotic) cells rather than early
apoptotic cells. For example, late apoptosis increased
significantly from less than 20% to more than 60%
when the concentration of Deguelin increased from
5 μM to 50 μM.The apoptosis induced by Deguelin is mediated through
a ROS-driven Akt pathway
Western blot analysis revealed that Deguelin could greatly
ameliorated the expression of p-Akt and p-GSK3β and
subsequently activated the caspase-3 pathway (Figure 4A).
Moreover, NAC significantly reduced the suppressive
effect of Deguelin on protein expression. In addition,
semi-quantitative analysis of the bands showed a signifi-
cant decrease in the expression of p-Akt and p-GSK3β as
the concentration of Deguelin increased, regardless of
co-treatment with NAC (p < 0.05) (Figure 4B & C). Most
importantly, significant differences were noted in the ex-
pression of p-Akt and p-GSK3β between the cells exposed
to single Deguelin treatment and combination treatment
with NAC. In comparison to control cells, the expression
of p-Akt was significantly reduced by more than 30% in
the cells treated with 5 μM Deguelin. Meanwhile, co-treatment with NAC restored p-Akt expression by nearly
20% (Figure 4B & C).
Additionally, the expression of cleaved Caspase-3, an
apoptotic indicator, increased dramatically during the
cellular exposure to two different doses of Deguelin
(Figure 4A). Co-treatment with NAC resulted in more than
20% reduction in the elevated levels of cleaved Caspase-3
observed in Deguelin-only treated cells (Figure 4D).
Discussion
As previously reported, tumor cells are vulnerable to the
induced ROS generation due to the insufficiency of anti-
oxidant mechanisms [24,27]. Intracellular ROS accumu-
lation by some chemotherapeutics is one of the most
important strategies of inducing the apoptosis of cancer
cells [28,29]. On the contrary, strengthening the antioxi-
dant capacity by introducing small ROS scavenging mole-
cules, such as NAC, will reduce the potential of the drug
to induce apoptosis. NAC is the most common used dis-
criminator to verify if cell death is associated with ROS.
Some studies show that NAC exhibits a concentration-
dependent inhibition on ROS induction [30]. However,
other studies demonstrate that NAC is a weak reducing
agent and a poor antioxidant compared with glutathione
(reduced form) (GSH) [31,32].
In our previous studies, we found that several herbal
medicines, such as Tetrandrine, Resveratrol, Ursolic acid,
etc., can influence the redox state of cancer cells by gener-
ating intracellular ROS, thereby contributing to cellular
apoptosis, which can be partially reversed by antioxidants,
such as NAC, Vitamin E [18,33-35]. Few studies to date
focus on the effects of Deguelin on the cellular redox
state. Only one study reported that Deguelin is capable of
rapidly diminishing the oxygen consumption by interfer-
ing with Complex I to trigger mitochondrial permeability
transition and result in an oxidative stress with excess
ROS, thereby leading to the apoptosis [36].
In the current study, Deguelin exerted an oxidative
stress on NCI-1975 cells by elevating the intracellular level
of ROS, which was partially reversed by co-treatment with
the antioxidant NAC. In the cytotoxicitity test, Deguelin
shows a dose-dependent inhibitory effect on the prolifera-
tion of NCI-1975 cells, while co-administration of NAC
resulted in partial rescue of some cells with an increased
survival rate. Further analysis of the intracellular ROS
levels reveals that Deguelin augments the generation of
intracellular ROS in a dose dependent manner. Similarly,
antioxidant NAC co-treatment partially blocks the stimu-
lating effect of Deguelin in ROS generation. Though there
was only 10% reduction of ROS production under the
treatment of NAC, it still generated statistically significant
reversal effect against the cytotoxicity of Deguelin. It
means that ROS elevation is significant to the cytotoxicity
of Deguelin. A subtle alteration of ROS levels can lead to
Figure 2 Influence of Deguelin on the cell proliferation. A: Hoechest and Edu dual staining of NCI-1975 cells under the treatment of a series
of Deguelin with or without the presence of NAC. A: Image of dual staining of cells treated by Deguelin only. B: Image of dual staining of cells
treated by Deguelin with the presence of NAC (500 μM). C: Quantification of proliferative cells under the treatment of Deguelin with or without
the presence of NAC. # represents p < 0.05 vs the corresponding dose between cells without and with the treatment of NAC. ** represents p < 0.01 vs
the control cells. Data are presented as mean ± SD (n = 3).
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Figure 3 Apoptosis induced by Deguelin. A: Apoptosis rates induced by Deguelin with or without the co-treatment of NAC by FACS. B: Quantification
of apoptotic cells induced by Deguelin with or without the co-treatment of NAC. # represents p < 0.05 vs the corresponding dose between cells without
and with the treatment of NAC. ** represents p < 0.01 vs the control cells. Data are presented as mean ± SD (n = 3).
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fore, like other herbal medicines, Deguelin possesses the
ability to induce cellular oxidative stress, offering a prom-
ising potential therapeutic for lung cancer therapy.
Previous studies have demonstrated that Deguelin could
induce both early and late apoptosis at certain concentra-
tions [4]. However, our results provided another possibility
of Deguelin’s effect. FCAS analysis showed that Deguelin
induced more late apoptosis (necrosis) than early apop-
tosis, which is a very interesting phenomenon. Literature
search in the database showed that in addition to apop-
tosis, Deguelin could induce autophagay, another kind of
cell death, to inhibit the growth of cancer cells [37].
Therefore, it is possible that the cytotoxicity of Deguelin
not only involves cell apoptosis but also other kinds of cell
death, such as autophagy. Further studies needs to be per-
formed to clarify this phenomenon.PI3k/Akt, one of the main mediators of survival signals
preventing cells from undergoing apoptosis, tends to be a
potential target for cancer therapy [38,39]. Previous stud-
ies focused on the antitumor effect of PI3k/Akt inhibitors,
such as LY294002 and wortmannin, etc. [40,41]. However,
the toxicity and poor solubility of these inhibitors still pose
a major barrier for further application. Previous studies re-
ported that Deguelin, a naturally occurring herbal medi-
cine, inhibits the phosphorylation of Akt and induces
apoptosis in a series of cancers, such as lung, head and
neck, gastric cancer etc. [4,42]. In addition, the current
findings are also valuable to overcome the emerging resist-
ance to chemotherapeutics in cancer cells. Earlier studies
have demonstrated that drug resistance is closely related
to the activation of PI3k/Akt pathway [43,44]. Thus,
Deguelin, as a natural PI3k/Akt inhibitor, seems to be a
novel antitumor drug targeting the Akt pathway.
Figure 4 Relative protein expression under the treatment of Deguelin. A: Gel image of Western blot analysis showing the related protein
expression in NCI-1975 cells exposed to Deguelin (5 and 20 μM) with or without the presence of NAC. B: Bar graph representing the semi-
quantification of gel image (p-Akt/Akt) normalizing the band with the GAPDH control. # represents p < 0.05 vs the corresponding dose between
cells without and with the treatment of NAC. ** represents p < 0.01 vs the control cells. Data are presented as mean ± SD (n = 3). C: Bar graph
representing the semi-quantification of gel image (p-GSK3β/GSK3β) normalizing the band with the GAPDH control. # represents p < 0.05 vs the
corresponding dose between cells without and with the treatment of NAC. ** represents p < 0.01 vs the control cells. Data are presented as
mean ± SD (n = 3). D: Bar graph representing the semi-quantification of gel image (Caspase-3) normalizing the band with the GAPDH control.
# represents p < 0.05 vs the corresponding dose between cells without and with the treatment of NAC. ** represents p < 0.01 vs the control cells.
Data are presented as mean ± SD (n = 3).
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seems to be a hierarchy in the relationship between ROS
and Akt, in which ROS tends to function as an upstream
signal for Akt [24,45,46]. In the current study, we demon-
strated for the first time that both the activity of PI3k/Akt
pathway and the cellular redox state are closely related to
the pharmacological effect of Deguelin. The antitumor ef-
fect of Deguelin is mediated through the ROS-driven
dephosphrylation of Akt, which indicates the potential of
Deguelin in the targeted therapy of ROS dependent PI3k/
Akt pathway. However, ROS detection by FCAS showed
that only 10% of ROS production was inhibited by NAC.
Though there is a significant difference between thepresence and absence of NAC, this partial reversal effect
of NAC still means ROS plays a key role in Deguelin’s an-
ticancer effect.
Future studies will be focused on the chemosensitization
effect of Deguelin. Previous studies show that accumula-
tion of ROS is a crucial step for Paclitaxel-induced cell
apoptosis, and that cellular antioxidant capacity plays a
key role in the chemoresistance of Paclitaxel [28]. Since
Deguelin is able to induce oxidative stress, it is reasonable
to hypothesize that Deguelin may sensitize cancer cells to
Paclitaxel through intracellular induction of ROS, which
can shed light on the novel chemosensitization strategy in
cancer therapy.
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We report in the current study that Deguelin, a natural
retinoid isolated from some plant species, effectively in-
hibits the growth and induces the apoptosis of NSCLC
NCI-1975 cells through the elevation of intracellular




Deguelin, 2,7-dichlorodihydrofluorescin diacetate (H2DCF-
DA), N-acetylcysteine (NAC), dimethyl sulfoxide (DMSO)
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan
(MTT) were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). Stock solutions of H2DCF-DA and
NAC were made in DMSO and sterilized by passage
through a 0.22 μm pore size filter (Immobilon, Millipore
Corp., Bedford, MA, USA), diluted with culture media be-
fore use. RPMI-1640 medium, fetal bovine serum (FBS)
and penicillin/streptomycin were purchased from Gibco
BRL (Grand Island, NY, USA). Annexin V-fluorescein iso-
thiocyanate (FITC) kit was purchased from Bender Med-
Systems (Vienna, Austria). Other reagents were of analytic
grade and obtained from Nanjing Chemical Reagent Co.
(Nanjing, China), unless otherwise described.
Cell culture
Human non small cell lung cancer cell line NCI-1975
was obtained from the Institute of Biochemistry and
Cell Biology, Chinese Academy of Sciences (Shanghai,
China). The cells were cultured in RPMI-1640 medium
supplemented with 10% FBS, 100 units/ml penicillin G,
and 100 μg/ml streptomycin at 37°C in a humidified in-
cubator with 5% CO2.
Methyl thiazolyl tetrazolium (MTT) assay
NCI-1975 cells were seeded into 96-well plates at a
density of 5 × 103 cells per well and incubated overnight
in 10% FBS RPMI 1640 medium. The cells were then
treated with a series of Deguelin (5, 10, 20, 50 μM) in
serum-free conditions for 24, 36 or 48 h, with or without
the co-treatment of NAC (500 μM). The cell prolifera-
tion was determined by the MTT assay as described in
our previous study [18,47]. The 50% inhibitory concen-
tration (IC50) was calculated using the dose–response
curve.
Edu staining for cell proliferation
NCI-1975 cells were treated with Deguelin (5, 10, 20,
50 μM) with or without the co-treatment of NAC
(500 μM) and then washed once with PBS. The cells
were stained with 300 μl 50 μM Edu solution for 2 hours
according to the protocol. Cells were then stained with
the DNA-specific fluorochrome Hoechst 33342. Afterincubation in the dark at 37°C for 15 min, the cells were
washed with PBS, air-dried, mounted with 90% (v/v) gly-
cerol, and examined using a fluorescence microscope
with an excitation/emission wavelength of 350/550 nm
(Olympus, Japan). Proliferative cells were identified by
counting the red cells in ten different fields.
Annexin V/propidium iodide staining
NCI-1975 cells were seeded in a cell culture dish and ex-
posed to a series of Deguelin (5, 10, 20, 50 μM) with or
without the co-treatment of NAC (500 μM) for 24 h.
Apoptosis in NCI-1975 cells was evaluated by annexin
V-FITC and propidium iodide (PI) staining using an
Annexin V-FITC kit according to the manufacturer’s
protocol. After incubation in the dark at room tempera-
ture for 15 min, the cells were immediately analyzed by
FACScan flow cytometer (Becton Dickinson, CA, USA).
Detection of intracellular ROS production
Intracellular ROS generation was detected using H2DCF-
DA as a fluorescent probe, which is a non-polar com-
pound that is converted into a non-fluorescent polar
derivative (H2DCF) by cellular esterases after incorpor-
ation into cells. Membrane-impermeable H2DCF is rapidly
oxidized to highly fluorescent 2′,7′-dichlorofluorescein
(DCF) in the presence of intracellular ROS. NCI-1975
cells were plated at a density of 1 × 106–7 in 6-well plates,
allowed to attach overnight, and exposed to Deguelin (5,
10, 20, 50 μM) with or without the co-treatment of NAC
(500 μM) for 24 h, followed by staining with 10 μM
H2DCF-DA for an additional 30 min, rinsed with PBS. In
another experiment, cells were pre-treated with NAC at
400 μM for 2 h and then treated with Deguelin. The fluor-
escent DCF intensity was quantified using a FACScan flow
cytometer (Becton Dickinson, CA, USA).
Western-blot analysis
NCI-1975 cells were grown to sub-confluence in 60 mm
dishes and thereafter cultured in serum-free medium for
24 h. The cells were then treated with Deguelin (5 and
20 μM) with or without the co-treatment of NAC
(500 μM) for 24 h. The proteins were extracted from
cells and western blot analyses were performed as
described in our previous reports. Antibodies used in-
clude rabbit anti-phospho-Akt (Ser 473), anti-Akt, anti-
pGSK3β, anti-Caspase-3 (Cell Signaling Technology,
Danvers, MA, USA); and mouse anti-β-actin (Sigma).
Goat anti-rabbit and anti-mouse IgG horseradish perox-
idase (HRP)-conjugated secondary antibodies were pur-
chased from the Jackson ImmunoResearch Laboratories
(West Grove, PA, USA). Bands were quantified using
densitometric image analysis software (Quantity One,
Bio-Rad, Hercules, CA, USA). The relative expression of
Xu et al. Cancer Cell International  (2015) 15:25 Page 8 of 9phospho-Akt (p-Akt) was normalized to total Akt
(t-Akt) level.
Statistical analysis
The data is shown as the mean ± standard deviation
(SD), and was analyzed either by Student’s t test or by
one-way analysis of variance (ANOVA) (SPSS version
11.0; SPSS Inc., Chicago, IL, USA). A probability value
of less than 0.05 was considered statistically significant.
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